(C-X-C motit) ligand 9 and (C-X-C motit) ligand 11(CXCL9andCXCL11),arepotent chemoattractants for activated T cells, and play an important role in T helper 1 (Th)1 cell recruitment in chronic hepatitis C. No study has evaluated CXCL9, together with CXCL11, circulating levels in patients with mixed cryoglobulinemia and hepatitis C (MC+HCV-p). The aim of the present study therefore was to measure serum CXCL9, and CXCL11levels, in MC+HCV-p, and to relate the findings to the clinical phenotype. Serum CXCL9 and CXCL11 were measured in 71 MC+HCV-p and in matched controls. MC+HCV-p showed significantly higher mean CXCL9 and CXCL11 levels than controls (P < 0.001, for both), in particular, in 32 patients with active vasculitis (P < 0.001). By defining high CXCL9 or CXCL11level as a value of at least 2 SD above the mean value of the control group (> 100 pg/mL): 89% MC+HCV-p and 5% controls had high CXCL9 (P < 0.0001, chi-square); 90% MC+HCV-p and 6% controls had high CXCL11 (P < 0.0001, chi-square). In a multiple linear regression model of CXCL9 vs age, ALT, CXCL11, only CXCL11 was significantly (r = 0.452, P < 0.0001) and independently related to CXCL9.
cells and tissues including monocytes/macrophages, neutrophils, keratinocytes, endothelial and epithelial cells (2) .
CXCLll binds CXCR3, but with a higher affinity (3) and potency (3) than CXCLlO and CXCL9. CXCLll expression is strongly increased in response to IFN-beta or IFN-gamma, and is presumed to be involved in pathologies characterized by the presence of activated T cells. CXCLll recruits activated Thl lymphocytes to sites of inflammation.
Recent evidence has shown that CXC alphachemokines (Thl), especially CXCLl 0, play an important role in the active phases of mixed cryoglobulinemia (MC). In fact, circulating CXCL 10 levels are particularly high in cryoglobulinemic patients with active vasculitis, suggesting a prevalence of the Th1 immune response in this phase (4) (5) (6) . Furthermore, CXCLl 0 is higher in cryoglobulinemic patients with autoimmune thyroiditis, compared to those without (7, 8) .
Many studies have linked a Thl immune response with MC and HCV infection. Thl response leads to increased IFN-gamma and TNF-alpha production that in tum stimulates CXCLl 0 secretion by the target cells, thus perpetuating the immune cascade. This process may lead to the appearance of MC in genetically predisposed subjects (9, 10) .
In HCV-chronic hepatitis (HCV-CH) infection, few studies have evaluated serum levels of CXCL9 or CXCLll, with discordant results. Increased circulating levels of CXCL9 were observed in some studies (11) (12) (13) (14) , while other studies were unable to show any significant difference with controls (15) . It has been shown that the most noteworthy changes in gene expression of HCV patients with first stage liver fibrosis mainly affected the transcriptional network regulated by IFNs, including IFN-gammainducible genes (CXCL9, CXCLlO, CXCLll) (16) . Furthermore, plasma levels of CXCL9, soluble TNF receptor (sTNFR)-l and sTNFR-2 were independently associated with liver histological changes, suggesting a role of TNF activation and Thl-type cell-mediated immune response in the pathogenesis ofHCV infection (13) . Moreover, high circulating levels ofCXCL1l were observed in some studies (11, 12, 17) ,while another study was not able to show any significant difference with controls (15) . In vitro, CXCL 11 mRNA and protein expression was inducible in Huh-7 cells following either IFN-alpha or -gamma stimulation and synergistically with TNF-alpha. Furthermore, transfection ofHuh-7 cells with either poly(I:C) or HCV RNA representing the HCV subgenomic replicon induced CXCLll mRNA expression (18) .
The above-mentioned studies suggest that CXCL9 and CXCL 11, which are potent chemoattractants for activated T cells, are produced by hepatocytes in the HCV-infected liver and play an important role in T-cell recruitment and ultimately in the pathogenesis of HCV-CH.
No study has evaluated CXCL9, together with CXCLll, circulating levels in MC+HCV The aim of the present study therefore was to measure serum CXCL9, and CXCLll levels in patients with MC+HCV, and to relate the findings to the clinical phenotype.
MATERIALS AND METHODS

Patients
Seventy-one MC+HCV patients [45 F and 26 M; mean age 60±12 Standard Deviation (SD) years, age range 38-84 years; mean disease duration 11±13 SD years], consecutively referred to our Rheumatology Unit, were recruited for the study between 2002 and 2006. The diagnosis of MC+HCV was based on the presence of serum mixed (IgG-IgM) cryoglobulins and the classical clinical triad -purpura, weakness, arthralgias -and on the exclusion of other well-known systemic disorders, such as immuno-rheumatic and neoplastic diseases.
The study included only MC+HCV patients, without liver cirrhosis or hepatocellular carcinoma (by histology, laboratory evidence of liver failure and/or ultrasoundproven portal hypertension) (4, 6, 8) , in whom a thyroid screening [history, physical examination, thyrotropin, free triiodo-thyronine, free thyroxine, anti-thyroglobulin and anti-thyroid peroxidase antibodies measurements, and neck ultrasonography] excluded the presence ofassociated thyroid autoimmune disorders, a well known cause of high serum CXCLlO (7). Sixty-three % MC+HCV patients underwent liver biopsy for diagnostic purposes; liver histology activity index (grade), or stage of liver fibrosis were evaluated as reported previously (19) . The mean activity index (grade) in MC+HCV patients was 4.5±1.l, and the stage was 2.0±0.9. Main demographic and clinico-serological features of MC+HCV patients are reported in Table I .
Of the 71 subjects, 29 had been previously treated with IFN-alpha (Roche SpA, Monza, Italy) for an average of 11 months (range 1 to 25), at a mean dosage of9.5 MU/ week; the time elapsed from the last course of IFN-alpha treatment ranged from 5 to 89 months (mean 35±21). No statistically significant differences were observed in the main demographic and clinico-serological features of MC+HCV patients treated or untreated with IFN-alpha.
At the time of the study, 46 MC+HCV patients were taking low doses of corticosteroids, 16 had previously been on corticosteroids and 9 had never been treated with corticosteroids. No MC+HCV patient had had plasma exchange treatment in the year previous to the study. In both patients and controls, a careful medical history was collected, in particular with regard to family history of thyroid disease, smoking habits and drugs. The presence of Raynaud's phenomenon, Sjogren's syndrome, skin ulcers, peripheral neuropathy, and renal and liver involvement in MC+HCV patients was evaluated, as previously described (4) . Routine blood chemistry was carried out by standard methods (4, 6, 8) .
Controls
Each of the 71 MC+HCV patients eligible for the study was matched, by sex and age, one-to-one with a control group of healthy subjects of the general population from the same geographic area (North-West Tuscany). This control group was extracted from a larger sample of 1,640 subjects in a population-based survey of thyroid disorders; only HCV-negative subjects, without any clinical or laboratory evidence of thyroid, liver disorders and autoimmune diseases and not treated with immunomodulators were included.
Extraction of the control group from the original populations was carried out by finding the closest age match (± 2 years) to each case ofeither gender. When more than one age-match was available per case, the choice was made at random.
The study protocol was approved by the local Ethics Committee. All patients and controls gave their informed consent to take part in the study.
Immunological studies
Cryocrit was measured as the percentage of packed cryoglobu1ins after cold centrifugation of the serum; cryoglobulin composition was determined by including the presence in cryoprecipitates of monoclonal or polyclonal IgM-rheumatoid factor (ie MC type II or MC type III); anti-nuclear, anti-smooth muscle and anti-mitochondrial autoantibodies were detected by current techniques (4, 6, 8) . Sera with a titre > 1:40 were considered positive. Antiextractable nuclear antigen antibodies, including antiScl-70 (topoisomerase-l), -Sm (smooth muscle antibody), -RNP (RNA-binding protein antibodies), -SSA (antibodies to SS-A antigen)/SSB (antibodies to SS-B antigen), -PCNA (proliferating cell nuclear antigen), -SL and Jo-l (istidil-tRNA sintetase) specificities, were detected by counter-immunoelectrophoresis (4, 6, 8) .
Virological studies
Anti-HCV antibodies and HCV RNA were determined on serum clotted and centrifuged at 37°C and stored at -70°C. Antibodies against HCV and HCV RNA (polymerase chain reaction technique) in the serum were investigated, as previously described (4, 6, 8) .
Chemokines analytical assays
Serum CXCL9 levels were assayed by a quantitative sandwich immunoassay using a commercially available kit (R&D Systems, Inc., Minneapolis, MN, USA), with a sensitivity ranging from 1.2-11.5 pg/ml, and a mean minimum detectable dose of 3.7 pg/mL. The intra-and inter-assay coefficients of variation were 4.0% and 7.1%.
Serum CXCLll levels were assayed by a quantitative sandwich immunoassay using a commercially available kit (R&D Systems), with a sensitivity ranging from 0.40-20.9 pg/mL and a mean minimum detectable dose of 11.7 pg/ml., The intra-and inter-assay coefficients of variation were 4.0% and 7.1%.
Samples were assayed in duplicate. Quality control pools of low, normal, or high concentration for all parameters were included in each assay. Alanine aminotransferase (ALT) was assayed by conventional methods (20) .
Data analysis
Values are given as mean ± SD for normally distributed variables, or as median ± interquartile range for not normally distributed variables. Group values were compared by univariate Analysis of Variance (ANOVA), for normally distributed variables; or by Kruskal-Wallis (:::: 3 groups) or Mann-Whitney U (2 groups) tests, proportions were compared by the chi-square test. Posthoc comparisons on normally distributed variables were carried out using the Bonferroni-Dunn test. Univariate analysis was performed by simple regression. A multiple linear regression model analysis using age and ALT, as independent variables and CXCL9 or CXCLll as dependent variables was performed.
RESULTS
The demographic and clinical features ofpatients are reported in Table I .
Patients with MC+HCV showed significantly higher mean CXCL9 serum levels than controls (409±203 vs 68±20 pg/ml., respectively; P< 0.0001, ANOVA) (Fig. I) . In order to better define the role of increased serum CXCL9 in MC+HCV, mean levels of this chemokine were separately evaluated (by ANOVA) among MC+HCV patient subgroups defined according to main demographic and clinical features (age> 55 years; gender; disease duration > 10 years; presence or absence of purpura, active vasculitis, weakness, arthralgias, arthritis, Raynaud's phenomenon, Sjogren's syndrome, peripheral neuropathy, renal involvement, aminostransferases elevation and/or histologic activity in the liver). Significantly higher levels of CXCL9 were observed in 32 patients with active vasculitis at the time of the present study in comparison to those without (763±3l6 vs 324±137 pg/mL, respectively; P < 0.001, ANOVA) (Fig. I) ; no other significant result was found. By defining high CXCL9 level as a value of at least 2 SD above the mean value of the control group (> 108 pg/mL), 89% of patients with MC+HCV and 5% of the controls had high CXCL9 levels (P < 0.0001 vs controls; chi-square). No significant correlations were observed between CXCL9 and serological findings ofMC+HCV (levels of cryocrit and complement, presence/absence of autoantibodies) or previous/ongoing treatments. Patients with MC+HCV showed significantly higher mean CXCL11 serum levels than controls (224±295 vs 63±14 pg/mL, respectively; P< 0.0001, ANOVA) (Fig. 2) . In order to better define the role of increased serum CXCL11 in MC+HCV, mean levels of this chemokine were separately evaluated (by ANOVA) among MC+HCV patients' subgroups defined according to main demographic and clinical features (age> 55 years; gender; disease duration > 10 years; presence or absence of purpura, active vasculitis, weakness, arthralgias, arthritis, Raynaud's phenomenon, Sjogren's syndrome, peripheral neuropathy, renal involvement, aminostransferases elevation and/or histologic activity in the liver). Significantly higher levels of CXCLlI were observed in 32 patients with active vasculitis at the time of the present study in comparison to those without (265±208 vs 179±62 pg/mL, respectively; P < 0.001) (Fig. 2) ; no other significant result was found. By defining high CXCLlI level as a value of at least 2 SD above the mean value of the control group (> 91 pg/mL), 90% ofpatients with MC+HCV and 6% of the control had high CXCLlI (P< 0.0001 vs controls; chi-square). No significant correlations were observed between CXCLlI and serological findings of MC+HCV (levels of cryocrit and complement, presence/absence of autoantibodies) or previous/ongoing treatments.
In particular, no significant difference was observed in CXCL9, or CXCLl1, levels between the 46 MC+HCV patients taking glucocorticoids, in respect to the 9 patients who had never received glucocorticoid therapy. Furthermore, among the 32 patients with active vasculitis, 27 were receiving corticosteroids treatment, while 5 had no therapy when chemokines were measured; no significant difference was observed in CXCL9 or CXCL11 levels between these two groups.
In a simple regression analysis, CXCL9 and CXCLll serum levels were significantly related to each other (r = 0.680, P < 0.0001) in MC+HCV patients (Fig. 3) . In a multiple linear regression model of CXCL9 (In[pg/mL]) vs age, ALT, and CXCLll (In[pg/mL]), only CXCLll [coefficient (beta), 0.234; coefficient (R.c.), 0.132; 95% lower, 0.031; 95% upper, 0.281; P value = 0.001] was significantly (r = 0.452, P < 0.0001), and independently related to CXCL9.
DISCUSSION
Our study demonstrates significantly high serum levels of CXCL9, in association with CXCLl1, in patients with MC+HCV compared to healthy controls. Interestingly, among MC+HCV the CXCL9 and CXCLll levels were significantly higher in patients with signs of active vasculitis compared to those without. Moreover, we have shown for the first time a strong association between CXCL9 and CXCLll circulating levels, strongly supporting the role of a Th1 immune response in the pathogenesis of MC+HCV.
Our results agree with those of other studies on patients with HCV infection without MC. Increased circulating levels of CXCL9 were observed in some studies (11) (12) (13) (14) , while another study was not able to show any significant difference with controls (15).
Discordant results have been reported in HCV-CH also for CXCL11.In fact, increased circulating levels of CXCLll were observed in some studies (11, 12, 17) , while another study was not able to show any significant difference with controls (15) . Bieche et at. (16) studied the expression of 240 genes in first stage of liver fibrosis in patients with HCV-CH infection. The most noteworthy changes in gene expression mainly affected the transcriptional network regulated by IFNs, including both IFN-alphalbeta-inducible genes (STATl, STAT2, etc.) andIFN-gamma-inducible genes (CXCL9, CXCLlO, CXCLll). Moreover, they showed mRNA level up-regulation for these genes. Furthermore, plasma levels of CXCL9, sTNFRl, and sTNFR2 were independently associated with liver histological changes, suggesting a role of TNF activation and Th1-type cell-mediated immune response in the pathogenesis ofHCV infection (13) . These results suggest that CXCL9, one of the most potent chemoattractants for activated T cells, is produced by hepatocytes in the HCV-infected liver and plays an important role in T-cell recruitment and ultimately in the pathogenesis ofHCV-CH.
In our MC+HCV patients, CXCL9 and CXCLll serum levels were significantly higher than in controls. The possible contribution of HCV-CH to high CXCL9 and CXCLll serum levels in MC+HCV patients cannot be excluded; in fact, CXCL9 and CXCLll are higher in MC+HCV patients without active vasculitis than in controls. However, the significantly higher serum CXCL9 and CXCLll in MC+HCV patients with active vasculitis compared to those without suggests that a further, significant increase of these chemokines, expression of a Thl immune response, is particularly relevant in the pathogenesis of cryoglobulinemic vasculitis. These data agree with those found in other not MC+HCV vasculitic syndromes (21) .
Furthermore, the increase ofCXCL9 in MC+HCV is in agreement with other recent evidence. In fact, circulating CXCLl 0 and CXCLll are high in cryoglobulinemic patients with active vasculitis, suggesting a prevalence of the Th1 immune response in this phase (4) (5) (6) 22) .
Changes ofserum chemokine levels in the course of other autoimmune disorders have been demonstrated. Recent experimental evidence has demonstrated that CXC chemokines, and particularly CXCLl 0, play an important physiopathological role in the initial phases of autoimmune thyroid disorders (23) (24) (25) , with an inverse correlation between circulating CXCLlO levels and disease duration in Graves' disease (GD). In our study we have not found any relation between serum CXCL9 or CXCLll levels and the duration of MC+HCV, probably because the disease is characterized by a relapsing clinical course the most common expression of which are vasculitic symptoms; these complications may appear at any time during the follow-up, possibly triggered by multiple pathogenetic co-factors (26) . Clinicopathological alterations of MC+HCV may recognize at least two synergical pathogenetic mechanisms triggered by HCY. Firstly, B-cell proliferation leads to immune-complex production, mainly HCVcontaining cryoglobulins, which are responsible for immune-complex-mediated vasculitis (26, 27) ; while high serum CXCL9 levels secondary to both HCV-relatedvascular and hepatic cell injury strongly amplify the inflammatory process through Th1-mediated immune response. The increase of CXCL9 and CXCLll in the active phase of the disease is in agreement with findings arisen from previous reports (28) in which serum CXCLl 0 has been found high in the .active phase of multiple sclerosis and Graves' Disease (29) . In particular, previously reported inverse correlation between CXCLl 0 levels and time from last clinical relapse together with the finding that CXCLl 0 is upregulated at disease onset and during relapse in multiple sclerosis (28) strongly supports this hypothesis. Furthermore, we have recently shown that increased serum CXCLIO levels in patients with GD are associated mainly with the active phase of GD, not related to hyperthyroidism itself, but mainly to the autoimmune response (29) .
More recently, it has been shown that high plasma CXCLl 0 levels correlate with a poor outcome of antiviral therapy in patients with HCV-CH. In fact, a low baseline CXCLl 0 level was significantly associated with low baseline viral load, rapid viral response, and sustained viral response in HCV-CH patients treated with IFN-alpha (11) . Furthermore, levels of CXCLl 0, CXCL9 and CXCLll were measured before, during, and after antiviral therapy in a group of 29 HCV-CH patients (11): CXCLlO and CXCL9 decreased following successful antiviral therapy, while CXCLll did not decline significantly during or in the first 6 months after therapy, suggesting a different behavior of these chemokines in relation to the treatment (11) . Since IFN-alpha is a well known effective therapy for MC+HCV (27) , longitudinal evaluation ofserum CXCL9 or CXCLlI might suggest the virological response to IFN also in MC+HCV patients.
A shift from the pro inflammatory Thl-type cytokine profile (IL-12, IL-2, TNF-alpha, IFNgamma) to the anti-inflammatory Th2-type cytokine profile (IL-lO, IL-4, IL-5, IL-13) in hypercortisolaemia, and pregnancy has been suggested (30) .
In our study no significant difference was observed.in CXCL9, or CXCLll, levels between the MC+HCV patients taking glucocorticoids, or not. However, more research is needed to finally clarify this interesting point.
Interestingly, to the best of our knowledge, this is the first demonstration of a strong relation between circulating CXCL9 and CXCL 11, in a human pathology, such as MC+HCV. This finding strongly supports the role of a Thl immune response in the pathogenesis ofMC+HCV.
In conclusion, our study demonstrates markedly high serum levels of CXCL9, and CXCLlI, in patients with MC+HCV compared to healthy controls; in MC+HCV patients increased CXCL9 and CXCLlI levels were significantly associated with the presence of active vasculitis. Moreover, a strong relation between circulating CXCL9 and CXCLll, in MC+HCV has been shown. Future studies on larger cohorts of patients will be needed to evaluate the relevance of serum CXCL9 and CXCLlI determination as clinico-prognostic marker of MC+HCV, as well as its usefulness in the therapeutic approach to these patients.
